Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
Mr James Downie, CEO, presented on the topic 'Independent Hospital Pricing Authority Update' at the HBN/CHASAN Steering Committee, hosted by Catholic Negotiating Alliance on 15 May 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the 2017 Activity-Based Funding Conference, hosted by the Health Service Executive, Ireland on 11 May 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
Mr James Downie, CEO, presented on the topic 'Independent Hospital Pricing Authority Update' at the HBN/CHASAN Steering Committee, hosted by Catholic Negotiating Alliance on 15 May 2017.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the 2017 Activity-Based Funding Conference, hosted by the Health Service Executive, Ireland on 11 May 2017.
What Happens After Your Device is Approved? Collecting Data in the Real WorldMedpace
In this workshop, Medpace will discuss key considerations for generating real-world evidence and how to apply critical insights in order to drive late-stage clinical research. To listen to this presentation, visit https://vimeo.com/168768256
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
Mr James Downie, CEO, presented on the topic 'IHPA 2017 and beyond' at the Enhancing Performance & Efficiency in Paediatric Care - CHA Annual Benchmarking Forum, hosted by Children's Healthcare Australasia on 25 May 2017.
Learn how to leverage effective strategies for global drug development, including expedited regulatory pathways, personalized medicines and genomics. View the full presentation from PAREXEL Consulting experts.
Paul Coplan, VP, Johnson & Johnson_mHealth IsraelLevi Shapiro
Pesentation, October 19th, 2021: What’s Next in RWE for Medical Devices: The Art of the Possible. Presented by Paul Coplan, ScD, MBA, FISPE, Vice President, Med Device Epidemiology and RWD Sciences, Johnson & Johnson; Adjunct Professor, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine; Fellow of the International Society of Pharmacoepidemiology
- Why RWE is Important for Medical Devices: Challenges with Clinical Trials of Medical Devices (Blinding, Surgeon skill/technique, Hospital process, Product modifications, Long term Follow up, Enrolment challenges)
- Types of Real-World Data Sources (Complaints like MAUDE, Eudramed and Company Databases, Hospital Databases, Electronic Health Records, Claims, Registries, Patient surveys, Surgeon surveys, PROs, Patient Preferences, wearables, sensors, social media, Surgical videos, device generated data, radiographic images)
- FDA CDRH Report on RWE Examples for Regulatory Decisions
- J&J Med Device Epidemiology & Real-World Data Sciences
- US National Evaluation System for Health Technology (NEST)
- RWE for Safety Assessments: Cobalt in Implants and at Work and Risk of Cancer
- Summary of Cobalt Exposure and All-Site Cancer Risk, by Study Type
- Comparative Effectiveness Studies Using RWE
- Summary
a. Use of RWE is important to benefit patients globally and enhance the safety and innovation of medical devices
b. Regulators are interested in using RWE for regulatory decisions but data quality and evidence needs to be regulatory grade
c. NEST has been a useful forum to advance the use of RWE for regulatory decisions in the US
d. RWE can be used for safety assessments, regulatory decisions, comparative effectiveness research, and R&D of products
Seamless Journey from Population Health to Precision MedicineOrion Health
Precision medicine is happening now! Join us as we examine the opportunities to leverage your initial core data sets and prepare for new data types to deliver real-time population health and precise medicine.
This webinar will demonstrate how modern healthcare organizations (HCO) are expanding clinical integration and upgrading to higher performing technology stacks on their journey to the omics-based and real-time delivery of precision medicine.
We’ll chat with Dr. Chris Hobson, CMO and CPO at Orion Health, Doctor Dylan Mordaunt, Clinical Director Research at Orion Health, and with Orion Health’s Executive Vice President of Product and Strategy, Dave Bennett about the importance of real-time data mining and re-mining, and which new computational tools and techniques you need to meet your population health goals and future proof your organization for the delivery of precision medicine.
In this webinar, we will explain:
How new models of medicine (e.g., molecular medicine, value-based medicine, etc.) are driving the immediate need for patient-specific decision support assistance
How existing and new data sets can be leveraged with integrated and real-time analytics (e.g., family history, pharmacogenics) for immediate reduction in adverse events and improved outcomes
How innovative organizations are answering this demand with high-performing technology
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Implementing American Heart Association Practice Standards for Inpatient ECG ...Allina Health
Implementing American Heart Association Practice Standards for Inpatient ECG Monitoring: An Interventional Study at Abbott Northwestern Hospital presented by Kristin Sandau, PhD, RN
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Two of the New York metro area’s largest provider organizations will share their experiences leveraging HIE as one of many tools to decrease fragmentation of care and improve patients’ experiences across acute and post-acute care settings for patients undergoing elective surgeries. Representatives from NYULMC and VNSNY will summarize their efforts to redesign more personalized specific care pathways and the central role played by the implementation of real-time data exchange to provide a seamless transfer of clinical data between providers caring for the patient at the time of discharge and throughout the post-acute period.
• Kathleen Mullaly - Senior Director for Clinical Operations, Department of Network Integration, NYU Langone Medical Center
• Amy Weiss - Director for Strategic Account Development, Integrated Delivery Systems, Visiting Nurse Service of New York (VNSNY)
New York eHealth Collaborative Digital Health Conference
November 18, 2014
What Happens After Your Device is Approved? Collecting Data in the Real WorldMedpace
In this workshop, Medpace will discuss key considerations for generating real-world evidence and how to apply critical insights in order to drive late-stage clinical research. To listen to this presentation, visit https://vimeo.com/168768256
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
Mr James Downie, CEO, presented on the topic 'IHPA 2017 and beyond' at the Enhancing Performance & Efficiency in Paediatric Care - CHA Annual Benchmarking Forum, hosted by Children's Healthcare Australasia on 25 May 2017.
Learn how to leverage effective strategies for global drug development, including expedited regulatory pathways, personalized medicines and genomics. View the full presentation from PAREXEL Consulting experts.
Paul Coplan, VP, Johnson & Johnson_mHealth IsraelLevi Shapiro
Pesentation, October 19th, 2021: What’s Next in RWE for Medical Devices: The Art of the Possible. Presented by Paul Coplan, ScD, MBA, FISPE, Vice President, Med Device Epidemiology and RWD Sciences, Johnson & Johnson; Adjunct Professor, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine; Fellow of the International Society of Pharmacoepidemiology
- Why RWE is Important for Medical Devices: Challenges with Clinical Trials of Medical Devices (Blinding, Surgeon skill/technique, Hospital process, Product modifications, Long term Follow up, Enrolment challenges)
- Types of Real-World Data Sources (Complaints like MAUDE, Eudramed and Company Databases, Hospital Databases, Electronic Health Records, Claims, Registries, Patient surveys, Surgeon surveys, PROs, Patient Preferences, wearables, sensors, social media, Surgical videos, device generated data, radiographic images)
- FDA CDRH Report on RWE Examples for Regulatory Decisions
- J&J Med Device Epidemiology & Real-World Data Sciences
- US National Evaluation System for Health Technology (NEST)
- RWE for Safety Assessments: Cobalt in Implants and at Work and Risk of Cancer
- Summary of Cobalt Exposure and All-Site Cancer Risk, by Study Type
- Comparative Effectiveness Studies Using RWE
- Summary
a. Use of RWE is important to benefit patients globally and enhance the safety and innovation of medical devices
b. Regulators are interested in using RWE for regulatory decisions but data quality and evidence needs to be regulatory grade
c. NEST has been a useful forum to advance the use of RWE for regulatory decisions in the US
d. RWE can be used for safety assessments, regulatory decisions, comparative effectiveness research, and R&D of products
Seamless Journey from Population Health to Precision MedicineOrion Health
Precision medicine is happening now! Join us as we examine the opportunities to leverage your initial core data sets and prepare for new data types to deliver real-time population health and precise medicine.
This webinar will demonstrate how modern healthcare organizations (HCO) are expanding clinical integration and upgrading to higher performing technology stacks on their journey to the omics-based and real-time delivery of precision medicine.
We’ll chat with Dr. Chris Hobson, CMO and CPO at Orion Health, Doctor Dylan Mordaunt, Clinical Director Research at Orion Health, and with Orion Health’s Executive Vice President of Product and Strategy, Dave Bennett about the importance of real-time data mining and re-mining, and which new computational tools and techniques you need to meet your population health goals and future proof your organization for the delivery of precision medicine.
In this webinar, we will explain:
How new models of medicine (e.g., molecular medicine, value-based medicine, etc.) are driving the immediate need for patient-specific decision support assistance
How existing and new data sets can be leveraged with integrated and real-time analytics (e.g., family history, pharmacogenics) for immediate reduction in adverse events and improved outcomes
How innovative organizations are answering this demand with high-performing technology
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Implementing American Heart Association Practice Standards for Inpatient ECG ...Allina Health
Implementing American Heart Association Practice Standards for Inpatient ECG Monitoring: An Interventional Study at Abbott Northwestern Hospital presented by Kristin Sandau, PhD, RN
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Two of the New York metro area’s largest provider organizations will share their experiences leveraging HIE as one of many tools to decrease fragmentation of care and improve patients’ experiences across acute and post-acute care settings for patients undergoing elective surgeries. Representatives from NYULMC and VNSNY will summarize their efforts to redesign more personalized specific care pathways and the central role played by the implementation of real-time data exchange to provide a seamless transfer of clinical data between providers caring for the patient at the time of discharge and throughout the post-acute period.
• Kathleen Mullaly - Senior Director for Clinical Operations, Department of Network Integration, NYU Langone Medical Center
• Amy Weiss - Director for Strategic Account Development, Integrated Delivery Systems, Visiting Nurse Service of New York (VNSNY)
New York eHealth Collaborative Digital Health Conference
November 18, 2014
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
Mr James Downie, CEO, presented on the topic 'IHPA 2017 and beyond' at the Enhancing Performance & Cost Effectiveness in Maternity & Women's Healthcare - Annual Benchmarking Meeting, hosted by Women's Healthcare Australasia on 26 May 2017.
Overview of the Patient-Centered Outcomes Research Institute (PCORI), how PCORI views Patient-Centered Outcomes Research and how this is related to PCORI’s major funding mechanisms.
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions.
The webinar was followed by an interactive question & answer session.
Public Reporting as a Catalyst for Better Consumer DecisionsATLAS Conference
Greater efficiency in the process of matching patients to appropriate providers is vital to achieving the Triple Aim. As patients research and choose among appropriate providers, sound decision-making will depend on the accessibility of high-quality data that enables them to make meaningful, actionable comparisons. Online public-reporting tools, such as those published by U.S. News, CMS and others, serve as venues for consumer decision-making. Driven by current trends in data transparency, rapid advances in public reporting can be anticipated. This presentation will outline several recent and expected future developments in the evolution of key public-reporting tools, and discuss their role in facilitating patient engagement and access to appropriate care.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
3. Current Emergency care
classifications
• Urgency Related Groups (URG):
‒based on type of visit, triage, episode end status
and diagnosis.
• Urgency Disposition Groups (UDG):
‒based on type of visit, triage and episode end
status.
• Limitations:
‒Both rely on triage (good indicator of urgency,
but not complexity/ resource use).
‒Limited clinical meaning.
3 www.ihpa.gov.au
4. Investigative review of
classification systems for
emergency care
• Commenced mid 2013, completed early 2014.
• Reviewed classifications developed/ used in Australia and
other countries:
‒Extensive clinical consultation.
‒Analysis of existing cost data.
• Conclusions:
‒New classification needed to replace URGs and UDGs.
‒Should be based on a high quality costing study.
‒Diagnosis given more importance and triage less.
‒Better account for patient complexity.
4 www.ihpa.gov.au
6. Development of a new
classification system for
emergency care
• Commenced mid 2015.
• Engaged consortium led by Health Policy Analysis.
• Key objectives:
‒Undertake a detailed costing study to investigate costs
associated with emergency care.
‒Develop a new patient-based classification system for
emergency care.
‒Modifications and enhancements to emergency care
data collections required to support the new
classification.
6 www.ihpa.gov.au
7. Costing Study Overview
• Inform classification development.
• Strong focus on consultation and clinically driven.
• All data provided to IHPA was de-identified and handled
in accordance with strict data governance processes.
• Ethics approval from the South Australian Human
Research Ethics Committee, and states/ territories also
obtained their own approvals.
• All sites in the study used barcode scanning technology
to record clinicians’ time spent with patients and the
activity/ procedure undertaken.
7 www.ihpa.gov.au
8. Costing Study Overview
• 10 sites from NSW, WA, SA, NT - included specialist
paediatric, major city and regional/remote hospitals.
• One month data collection between April to June 2016:
‒Two-week intensive collection of clinician time.
‒Investigations, procedures, presenting problem, and
other patient characteristics that impact on complexity
(termed ‘diagnosis modifiers’) were collected for the
whole four week period.
• Sites also submitted routinely collected data for the
remainder of the 2015-16 financial year.
8 www.ihpa.gov.au
9. Consensus study
of clinician time
• Undertaken in addition to the costing study data
collection.
• Aimed to estimate times for procedures and other
patient-related activities undertaken by ED clinicians.
• Estimates provided by approximately 300 clinicians
through Delphi process (medical, nursing, allied
health).
• Validate the results from the costing study and
potentially supplement data that might be missing for
specific procedures/ activities for any hospital.
9 www.ihpa.gov.au
10. Costing of data
• Activity data costed using project specific relative value
units (RVUs) based on clinician time data collected.
• Aligned with the Costing Standards/ NHCDC processes.
• Project specific working group established to ensure
consistency of costing was applied across sites.
• Validation processes to compare results from study with
standard processes to assess improvements.
• Further work to assess feasibility to implement outcomes
into future routine costing processes.
10 www.ihpa.gov.au
11. Costing study results
• Total of 43,175 presentations were captured during the
four week period; 21,765 of these attributed to two week
clinician time period.
• 83% of the presentations in two week clinician time
period had at least one procedure recorded;
approximately 8.4 procedures per ED patient stay.
• Overall mean cost per ED presentation for the study
period was $696 (median cost of $578).
• Components of overall direct costs included: medical
(26%), nursing (24%), imaging (11%), pathology (8%).
11 www.ihpa.gov.au
14. Costing study results
• Data demonstrated several variables collected are
correlated with higher costs:
‒more urgent triage categories
‒increasing age
‒patients that were admitted, referred to another
hospital or died in ED
‒indigenous status
‒confusion/agitation, unconsciousness, mental health
status.
14 www.ihpa.gov.au
17. Costing study results
• Four most commonly reported categories for ED
principal diagnosis: injuries (23% of total sample),
respiratory system disorders (11%), digestive system
disorders (11%) and circulatory system disorders (10%).
• Most common presenting problems included: abdominal
pain, chest pain, other specified problem, pain lower
limb/hip, review/medical assessment requested.
• Hospital level effects (e.g. role level/ specialisation and
location factors) impact on costs.
17 www.ihpa.gov.au
18. Costing study results – cont.
Cost by presence of diagnosis modifiers
18 www.ihpa.gov.au
19. Costing study results – cont.
Cost by episode end status category
19 www.ihpa.gov.au
22. Classification development
timeframes
• Classification development initial data analysis and data
development (Jun – Sept 2017).
• Consultation on the new classification and data
development recommendations (Sept – Dec 2017).
‒Public consultation period (Oct – Nov 2017).
• Finalisation of classification system, supporting
components and final report (early 2018).
• Implementation from 1 July 2019.
22 www.ihpa.gov.au
23. Further information
• IHPA website:
https://www.ihpa.gov.au/what-we-do/emergency-care
• Study website:
http://www.edclassificationstudy.com
• Email:
enquiries.ihpa@health.gov.au
23 www.ihpa.gov.au
Emergency department stays for Indigenous patients had higher costs compared with other patients ($728 versus $692). Subsequent analysis will need to consider the interaction with other factors (such as age), which may result in a larger difference in estimated mean costs.
The most common triage category overall is category four (Semi-urgent) (39.1%) followed by category three (Urgent) (38.2%). These categories account for close to 80% of emergency department stays in the sample.
There is a correlation between costs and triage categories, with the highest mean costs observed for patients assigned to category one ($1,518) and lowest for patients assigned to category five ($364).
There were variations in cost within episode end status categories (eg did not wait). It was noted that these cost differences were most likely due to local variation in practice, and that these will be explored in the next stage of the project.
Proportion of emergency department stays for which the diagnosis modifier was present was relatively low, ranging from below 1% to just over 10.5% at each hospital.